The production of glucagon-like peptide 1 (GLP-1), an incretin hormone, has been shown to be abnormally low in patients with type 2 diabetes, suggesting that GLP-1 may be a contributor in the pathogenesis of the disease. New type 2 diabetic medications target incretin hormones in their mechanism of action. The incretin effect is based on the understanding that oral glucose has a greater stimulatory effect on insulin secretion than that of intravenous glucose. Over the past few years, a number of therapeutic agents, acting either as incretin mimetics, e.g. GLP-1 agonists, or inhibitors of the breakdown of GLP-1, e.g. dipeptidyl peptidase-4 (DPP-4) inhibitors, have become available as treatment options for the management of type 2 diabetes. 
Introduction
It is estimated that 6.5% of adults aged 20-79 years have type 2 diabetes in South Africa. An age-adjusted prevalence of up to 13% has been described in urban populations. 1 The effects of urbanisation, lack of exercise and unhealthy eating habits have been found to be important contributors to the rising prevalence of type 2 diabetes, as well as obesity, in our country. 1 Type 2 diabetes is a progressive disease which may require intensification of therapy over time. Management includes a prudent diet, regular exercise and medicines to reduce blood glucose levels. Current pharmacological options in the management of type 2 diabetes include sulphonylureas, insulin, thiazolidinediones, alphaglucosidase inhibitors and metformin. These treatment options, although highly effective in reducing blood glucose levels, may be associated with an increased risk of hypoglycaemia, as seen with sulphonylureas and insulin; weight gain, as noted with insulin, sulphonylureas and thiazolidinediones; and gastrointestinal intolerance, as observed with metformin. These unwanted adverse effects may act as barriers to optimal glycaemic control. 2 As a result, newer and safer treatment options for optimal glycaemic control are continuously being investigated and developed. The glucagon-like peptide 1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are examples of such developments. This article will focus on the DPP-4 inhibitors, also known as the "gliptins", and their place in therapy in the management of type 2 diabetes.
A closer look at incretin hormones and dipeptidyl peptidase-4 inhibitors DPP-4 inhibitors are a new class of medicine which work to potentiate the effect of incretin hormones. Incretin hormones are secreted from the gastrointestinal tract (the enteroendocrine cells), into the bloodstream in response to food intake. The two most well-characterised incretin hormones are the GLP-1 and glucose-dependent insulinotropic polypeptide, also known as gastric inhibitory peptide (GIP).
When blood glucose levels are elevated following a meal, incretin hormones are released from the gastrointestinal tract, and they:
• Stimulate insulin secretion from the pancreatic β-cells
• Reduce glucagon secretion from the pancreatic α-cells
• Improve β-cell function • Slow gastric emptying 2, 3 Two of the many physiological roles of the incretin hormones as described above are to increase insulin secretion by the pancreatic β-cells and to suppress glucagon secretion by pancreatic α-cells. GLP-1, in particular, appears to be responsible for the majority of the incretin effects on pancreatic β-cell function. 2, 3 The net effect is increased peripheral glucose uptake and reduced hepatic glucose output which leads to improved glycaemic control. Figure  1 provides a schematic representation of the effect of incretin hormones on glycaemic control.
Circulating levels of GLP-1 are low in the fasting state, and rise quickly following a meal. In patients with type-2 diabetes, GLP-1 production is reduced. GLP-1 has a very short half-life and is rapidly degraded by the enzyme, dipeptidyl peptidase-4 (DPP-4). [2] [3] [4] [5] [6] In an attempt to harness the beneficial effects of GLP-1, research has focused on interventions along the GLP-1 pathway. The result of this research has been the development of GLP-1 agonists, e.g. exanetide and liraglutide, as well as the DPP-4 inhibitors. The DPP-4 inhibitors prolong the action of endogenous incretins, enhancing the insulin response.
GLP-1 agonists have a protein-based structure, and although they have longer half-lives than endogenous GLP-1, they require parenteral administration as is the case with exenatide (Byetta ® ) and liraglutide (Victoza ® ).
Both of these are available as pen devices. 1, 3, 4, 7 In contrast, DPP-4 inhibitors are smaller molecules that can be absorbed intact from the gastrointestinal tract, making oral administration possible. 3 Despite their common mechanism of action, the DPP-4 inhibitors show marked differences in their chemical structure. 2, 4, 6 This may explain some of the variance in the pharmacokinetic profiles of these products.
Drug interaction profile
In general, DPP-4 inhibitors do not interfere with cytochrome P450 (CYP450) enzymes. They are neither inhibitors nor inducers. The exception is saxagliptin (Onglyza ® ), which is metabolised by the CYP3A4/5 isoform into a primary active metabolite. 8, 11 As a result, saxagliptin may require dosage adjustment if taken concurrently with CYP3A4/5 inhibitors, such as ketoconazole, itraconazole, indinavir, nelfinavir, ritonavir and saquinavir. 1, 8, 9 The absence of significant drug-drug interactions with this class of medicine can be explained by their favourable pharmacokinetic characteristics and their low plasmaprotein binding.
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Safety profile DPP-4 inhibitors have been generally well-tolerated in short-term studies. Commonly reported adverse effects include nasopharyngitis (inflammation of the nasal passages and upper part of the pharynx), urinary tract infections, pancreatitis and headaches. Serious allergic reactions have been reported, including anaphylactic reactions, angioedema and exfoliative dermatological reactions. [1] [2] [3] [4] [5] 9 The incidence of hypoglycaemia is low, but may be increased when DPP-4 inhibitors are used in combination with other antidiabetic agents such as insulin or sulphonylureas. 9 The DPP-4 inhibitors also appear to be less likely to be associated with weight gain. DPP-4 inhibitors should be used with caution in patients who have a history of pancreatitis. DPP-4 inhibitors should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.
Since these products are fairly new on the market, longterm, real-life experience with their use is needed to further confirm their safety profile.
Available dipeptidyl peptidase-4 inhibitors
Various DPP-4 inhibitors are at different stages of development and registration across the globe. These 7, [10] [11] [12] [13] Linagliptin is registered in the US as Tradjenta™ and in Europe as Trajenta™. Table 1 lists examples of dipeptidyl peptidase-4 inhibitors.
The place of dipeptidyl peptidase-4 inhibitors in therapy
DPP-4 inhibitors are effective as monotherapy, and also in combination with other oral antidiabetic agents. Plasma DPP-4 inhibition profiles are consistent with once-daily dosing for all members of this class, with the exception of vildagliptin. 2, 8, 9 DPP-4 inhibitors are contraindicated where there is:
• Compelling indication for insulin therapy.
• A history of a serious hypersensitivity reaction to DPP-4 inhibitors.
• Patients with a history of acute pancreatitis, chronic or recurring pancreatitis, and those with pancreatic cancer.
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Conclusion
The development of DPP-4 inhibitors, which potentiate the incretin hormones by inhibiting the enzyme that is 
